EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects

Ahmad Karzoon iD, Mükerrem Betül Yerer iD, Ahmet Cumaoğlu iD

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-024-03316-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Ahmad Karzoon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye. 4020541801@erciyes.edu.tr. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Tamoxifen, Breast Neoplasms, Glucosides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erciyes University Scientific Research Foundation, Erciyes University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accumulating evidence suggests that sodium–glucose cotransporter 2 (SGLT2) inhibitors may be effective at eliminating tumor cells. While empagliflozin exhibits nearly the highest selectivity for SGLT2 over SGLT1, its specific impact alone and in combination with tamoxifen remains largely unexplored in estrogen receptor α-positive (ERα +) breast cancer. This study investigated the anticancer effects of empagliflozin and its potential synergy with tamoxifen in MCF-7 breast cancer cells. The individual and combined cytotoxic effects of empagliflozin and tamoxifen were assessed using the xCELLigence system. The activities of AMP-activated protein kinase α (AMPKα), p38 mitogen-activated protein kinase (p38 MAPKα), p70-S6 kinase 1 (p70S6K1), and protein kinase B (Akt) were assessed using Western blotting. The gene expression levels of peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) and Forkhead box O3a (FOXO3a) were assessed via qPCR. Our results revealed time- and concentration-dependent cytotoxic effects of empagliflozin and tamoxifen whether administered separately or in combination. While tamoxifen exhibits potency with an IC 50 value of 17 μM, approximately ten times greater than that of empagliflozin (IC 50 = 177 μM), synergistic effects are observed when the concentrations of the two agents approach their respective IC 50 values. Additionally, empagliflozin significantly increases AMPKα activity while concurrently inhibiting Akt, p70S6K1, and p38 MAPKα, and these effects are significantly enhanced when empagliflozin is combined with tamoxifen. Moreover, empagliflozin modulates the gene expression, downregulating PGC-1α while upregulating FOXO3a. Empagliflozin exerts anti-proliferative and anti-survival effects by inhibiting mTOR, Akt, and PGC-1α, and it exhibits synergy with tamoxifen in MCF-7 breast cancer cells. Graphical Abstract Proposed anticancer mechanism of empagliflozin in MCF-7 breast cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsTamoxifenBreast NeoplasmsGlucosidesEstrogen Receptor alphaSodium-Glucose Transporter 2 InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansDrug SynergismMCF-7 CellsCell ProliferationFemaleCell SurvivalProto-Oncogene Proteins c-aktPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRibosomal Protein S6 Kinases, 70-kDa

Stichwörter der Autor:innen

AktERα + breast cancerEmpagliflozinFOXO3aPGC-1αp70S6K1

Substanzen

empagliflozinBenzhydryl CompoundsTamoxifenGlucosidesEstrogen Receptor alphaProto-Oncogene Proteins c-aktSodium-Glucose Transporter 2 InhibitorsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRibosomal Protein S6 Kinases, 70-kDaESR1 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye. 4020541801@erciyes.edu.tr.
  • Drug Application and Research Center (ERFARMA), Department of Pharmacology, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye.
  • Department of Biochemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Türkiye.

ORCID-Profile: Ahmad Karzoon, Mükerrem Betül Yerer, Ahmet Cumaoğlu

Förderung

  • Erciyes University Scientific Research Foundation
  • Erciyes University

Zitieren

APA

Karzoon, A., Yerer, M. B., & Cumaoğlu, A. (2025). Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03316-z

Vancouver

Karzoon A, Yerer MB, Cumaoğlu A. Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03316-z

BibTeX
@article{Karzoon2025,
  author = {Karzoon, Ahmad and Yerer, Mükerrem Betül and Cumaoğlu, Ahmet},
  title = {Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-024-03316-z}
}
Kostenlos starten →